Vendor Intelligence Report: FSD

Published 3 Jul 2026. 18-page investigative report on who is behind FSD: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 5 Finnrick lab tests, FSD posts 5 pass / 0 fail, an overall pass rate of 100%. That headline is clean, but narrow: every Finnrick result in this dossier is Retatrutide. Retatrutide is therefore the only FSD product with Finnrick support here, and the report's methodology-sensitivity chart shows how that product's rating moves as grading thresholds tighten.

The risk picture is not a simple green light. A 536 EU, forum-documented Janoshik endotoxin warning attached to a Retatrutide 30mg batch sits outside Finnrick's purity/fill pass count, and SS-31 has a separate visible-particulate thread. For buyers, the report reads FSD at the product-and-batch level: Retatrutide has the measured support, but Retatrutide 30mg needs endotoxin clearance and untested catalog items should not inherit the rating.

The identity layer is weaker than the lab headline. FSD presents as Shanghai Fushida Chemical, but registry searches, domain forensics, and professional-profile checks did not validate a manufacturer entity, official storefront, address, or named principals. The live anchor is a 2,739-member peptide.chat/Revolt community, while Telegram, Gmail/ProtonMail, and a UK-format WhatsApp number carry much of the observed sales surface.

The full investigation also follows source-chain fingerprints: an FSD lilac-cap Retatrutide presentation aligns with a QST Retatrutide batch, and a matching endotoxin value brings JEEP into the comparator map without proving common ownership. The conclusion is directional: buy the batch, not the brand, and require verifiable lab documentation before treating any FSD item as cleared.

Inside the full report:

  • Appendix A product-by-methodology Finnrick laboratory table and methodology-divergence chart for Retatrutide
  • Dated event trail from the MESO-Rx launch to the live peptide.chat/Revolt capture
  • Chinese registry checks, domain-forensics negatives, and official-channel authentication guidance
  • Batch-specific contamination review covering Retatrutide 30mg endotoxin and SS-31 particulate reports
  • Source-chain comparison of FSD, QST, JEEP, and Andys signals
  • Payment rails, shipping claims, and buyer-recourse assessment

Risk assessment

  • Endotoxin-contamination concern — Retatrutide 30mg FSD0706 and reported Tirzepatide 30mg black cap — high: GLP-1 Forum reported FSD Retatrutide 30mg batch FSD0706 at 536 EU via Janoshik, with separate elevated-endotoxin reports for Tirzepatide 30mg black cap; use only with batch-level endotoxin clearance.
  • Particulate-contamination concern — SS-31 10mg white cap — medium: May 2026 GLP-1 Forum reports described visible particles later identified by MS as PVDF or Mannitol; injectable particulates indicate filtration/sterility-control failure.
  • Unverifiable corporate/manufacturer identity concern — medium: No registry match for Shanghai Fushida Chemical Co., Ltd.; no official website/address, and a UK WhatsApp number conflicts with the Shanghai manufacturer presentation.
  • Shared-upstream/source-control concern — Retatrutide 30mg — medium: FSD R30’s 536 EU value matched JEEP T30 and its lilac cap matched QST R30 batch 25Ja01; records suggest reseller/shared-source exposure rather than independent manufacturing.